Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

Studied

A double-blind placebo-controlled trial randomized adults after successful intensive lifestyle weight loss to weekly tirzepatide or placebo.

Who / model

Adults had overweight or obesity with an obesity-related complication, no diabetes, and prior successful weight loss during intensive lifestyle intervention.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Tirzepatide produced substantial additional weight loss and more participants reached the additional weight-loss threshold than with placebo.

Limits

Gastrointestinal events were the most common adverse events, although most were mild to moderate.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary